Navigation Links
Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors
Date:10/25/2007

SAN DIEGO, Oct. 25 /PRNewswire/ -- Novocell, Inc., a leading stem cell engineering company, today announced the appointment of Orville G. Kolterman, M.D., Senior Vice President, Clinical & Regulatory Affairs of Amylin Pharmaceuticals, to the company's Board of Directors.

Dr. Kolterman joined Amylin in 1992 and has served as Senior Vice President, Clinical Affairs since February 1997 until present and as Senior Vice President, Regulatory Affairs since August 2005. At Amylin, Dr. Kolterman has been instrumental in the development of the company's first-in-class diabetes medicines, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection.

"Dr. Kolterman's breadth of experience, including the clinical development of successful diabetes therapeutics, will be invaluable to Novocell as we advance the development of our diabetes cell therapy and additional cell therapies," said Alan J. Lewis, President, Chief Executive Officer and Director of Novocell.

"I am pleased to join the Novocell board and look forward to working with the Company to help advance it's innovative platform technologies, including its human embryonic stem cell engineering, cell encapsulation and drug discovery efforts, which hold promise for the treatment of a range of chronic diseases," said Dr. Kolterman.

Prior to Amylin, Dr. Kolterman was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California, San Diego (UCSD) Medical Center. He has also served as Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver and was a member of the Diabetes Control and Complications Trial Study Group. Dr. Kolterman currently serves as a member of the Epidemiology of Diabetes Intervention and Complications Study. He is also a past-president of the California Affiliate of the American Diabetes Association. Dr. Kolterman received his M.D. from Stanford University School of Medicine.

About Novocell

Novocell is a stem cell engineering company with research operations in San Diego, CA, and Athens, GA, dedicated to creating, delivering, and commercializing cell and drug therapies to treat diseases including diabetes. Novocell is the first company to efficiently engineer human embryonic stem cells into definitive endoderm, the gatekeeper cells that differentiate into many other cells, tissues and organs. Novocell is focused on the development of a variety of technology platforms including stem cell engineering, cell encapsulation, and drug discovery. The company was founded in 1999 and merged with CyThera, Inc. and BresaGen, Inc. in 2004. For more information, visit http://www.novocell.com.

Media Contact:

Julie Rathbun

Rathbun Communications, Inc.

julie@rathbuncomm.com

(206) 769-9219


'/>"/>
SOURCE Novocell, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 ... the region,s trusted information source for community, health and ... San Diego) will integrate to enhance care coordination ... people to the services they need and to better ... to improve care.   San Diego ...
(Date:2/4/2016)... New FDA action date of July 22, ... July 22, 2016   --> - ... - Lifitegrast has the potential to be the only ... signs and symptoms of dry eye disease in adults --> ... approved in the U.S. in the past decade indicated for the treatment of ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology:
(Date:2/4/2016)... 2016 The field of Human Microbiome ... most popular hubs of the biotechnology industry. While ... studies of human microbiota, have garnered a lot ... microbiome space has literally exploded in terms of ... report focuses on biomedical aspects of research, development, ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 Technology ... service presents an analysis of the digital and computed ... Malaysia , and Indonesia ... current trends and market size, as well as regional ... by country and discusses market penetration and market attractiveness, ...
Breaking Biology News(10 mins):